Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold

UBS analyst Michael Yee maintained a Hold rating on Biogen on February 6 and set a price target of $185.00.

Michael Yee has given his Hold rating due to a combination of factors, balancing Biogen’s solid near‑term performance with uncertainty around its longer‑term growth drivers. The company beat expectations in the latest quarter and issued 2026 earnings guidance ahead of consensus, but overall revenue is still projected to decline as the multiple sclerosis franchise erodes and only partially offsets with newer products.

At the same time, Biogen’s investment story is increasingly tied to several high‑impact but unproven pipeline events in 2026 and beyond, including mid‑year Phase II data for the tau‑targeting BIIB‑080 in Alzheimer’s, a late‑stage lupus trial, and an earlier‑stage Parkinson’s program with higher risk. While these assets could unlock meaningful upside if successful, mixed industry experience with tau therapies, competitive pressure in Alzheimer’s from Eli Lilly’s Kisunla, and a lengthy reimbursement timeline for Leqembi’s subcutaneous formulations justify a more neutral stance until data clarity improves.

In another report released yesterday, TipRanks – OpenAI also downgraded the stock to a Hold with a $215.00 price target.

BIIB’s price has also changed dramatically for the past six months – from $129.340 to $201.180, which is a 55.54% increase.